Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bipartisan Support Pushes FDA User Fee Bill One Step From Passage

This article was originally published in The Tan Sheet

Executive Summary

The Senate is expected to vote this week on the bipartisan compromise of the FDA user fee and reform legislation, which the House overwhelmingly passed in a voice vote June 20. Senate review of the bill will coincide with the Supreme Court’s decision on the health care reform law.

Advertisement

Related Content

FDA Drug Detention Regulation Follows Devices Oversight Model
FDA Drug Detention Regulation Follows Devices Oversight Model
FDA Could Publish Drug GMP Data To Nudge Manufacturing Improvements
FDA Could Publish Drug GMP Data To Nudge Manufacturing Improvements
Sequestration Could Drive An FDA Resources Review
Sequestration Could Drive An FDA Resources Review
In Brief
User Fee Conference Committee Targets Settling Differences In June
Coalition Pushes Congress On OTC Purchases With Health Savings Accounts
News In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS105813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel